Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan simulated driving performance in healthy volunteers
NCT03459612Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Standard Deviation of Lateral Position at 24 hours. Started Mar 2018; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03459612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459612.